Zinc pyrithione is a potent inhibitor of PL^Pro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication

References

• Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021;19:141–54.
   PubMed Web of Science ®Google Scholar
• Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565–74.
   PubMed Web of Science ®Google Scholar
• Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020;581:221–4.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Pöhlmann S. How SARS-CoV-2 makes the cut. Nat Microbiol 2021;6:828–9.
   PubMed Web of Science ®Google Scholar
• V'kovski P, Kratzel A, Steiner S, et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol 2021;19:155–70.
   PubMed Web of Science ®Google Scholar
• COVID-19 treatments: authorised. European Medicines Agency; 2021 [Internet] [cited 2021 Dec 17]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-treatments
   Google Scholar
• Coronavirus (COVID-19). Drugs. FDA; 2021 [Internet] [cited 2021 Dec 17]. Available from: https://www.fda.gov/drugs/emergency-preparedness-drugs/coronavirus-covid-19-drugs
   Google Scholar
• Bakowski MA, Beutler N, Wolff KC, et al. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. Nat Commun 2021;12:3309.
   PubMed Web of Science ®Google Scholar
• Sacco MD, Ma C, Lagarias P, et al. Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L. Sci Adv 2022;6:eabe0751.
   Web of Science ®Google Scholar
• Bafaro E, Liu Y, Xu Y, Dempski RE. The emerging role of zinc transporters in cellular homeostasis and cancer. Signal Transduct Target Ther 2017;2:1–12.
   Web of Science ®Google Scholar
• Skalny AV, Rink L, Ajsuvakova OP, et al. Zinc and respiratory tract infections: perspectives for COVID-19 (review). Int J Mol Med 2020;46:17–26.
   PubMed Web of Science ®Google Scholar
• Chinni V, El-Khoury J, Perera M, et al. Zinc supplementation as an adjunct therapy for COVID-19: challenges and opportunities. Br J Clin Pharmacol 2021;87:3737–46.
   PubMed Web of Science ®Google Scholar
• Marreiro DdN, Cruz KJC, Oliveira Ad, et al. Antiviral and immunological activity of zinc and possible role in COVID-19. Br J Nutr 2022;127:1172–8.
   PubMed Web of Science ®Google Scholar
• Moseley HNB. Current evidence supporting the use of orally administered zinc in the treatment of COVID-19. OSF Preprints; 2020.
   Google Scholar
• Asl SH, Nikfarjam S, Majidi Zolbanin N, et al. Immunopharmacological perspective on zinc in SARS-CoV-2 infection. Int Immunopharmacol 2021;96:107630.
   PubMed Web of Science ®Google Scholar
• Komai M, Goto T, Suzuki H, et al. Zinc deficiency and taste dysfunction; contribution of carbonic anhydrase, a zinc-metalloenzyme, to normal taste sensation. BioFactors 2000;12:65–70.
   PubMed Web of Science ®Google Scholar
• Equils O, Lekaj K, Wu A, et al. Intra-nasal zinc level relationship to COVID-19 anosmia and type 1 interferon response: a proposal. Laryngoscope Investig Otolaryngol 2021;6:21–4.
   PubMed Web of Science ®Google Scholar
• Mayor-Ibarguren A, Busca-Arenzana C, Robles-Marhuenda Á. A hypothesis for the possible role of zinc in the immunological pathways related to COVID-19 infection. Front Immunol 2020;11:1736.
   PubMed Web of Science ®Google Scholar
• Wessels I, Rolles B, Rink L. The potential impact of zinc supplementation on COVID-19 pathogenesis. Front Immunol 2020;11:1712.
   PubMed Web of Science ®Google Scholar
• Brewer J, Gomez Marti JL, Brufsky A. Potential interventions for SARS-CoV-2 infections: zinc showing promise. J Med Virol 2021;93:1201–3.
   PubMed Web of Science ®Google Scholar
• Zoghi S, Khamirani HJ, Dastgheib SA, et al. An analysis of inhibition of the severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase by zinc ion: an in silico approach. Future Virol 2021;16:331–9.
   Web of Science ®Google Scholar
• Pormohammad A, Monych NK, Turner RJ. Zinc and SARS CoV 2: a molecular modeling study of Zn interactions with RNA dependent RNA polymerase and 3C like proteinase enzymes. Int J Mol Med 2021;47:326–34.
   PubMed Web of Science ®Google Scholar
• Grifagni D, Calderone V, Giuntini S, et al. SARS-CoV-2 Mpro inhibition by a zinc ion: structural features and hints for drug design. Chem Commun 2021;57:7910–3.
   PubMed Web of Science ®Google Scholar
• Panchariya L, Khan WA, Kuila S, et al. Zinc2+ ion inhibits SARS-CoV-2 main protease and viral replication in vitro. Chem Commun 2021;57:10083–6.
   PubMed Web of Science ®Google Scholar
• te Velthuis AJW, van den Worml SHE, Sims AC, et al. Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog 2010;6:e1001176.
   PubMed Web of Science ®Google Scholar
• Ramajayam R, Tan K-P, Liang P-H. Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery. Biochem Soc Trans 2011;39:1371–5.
   PubMed Web of Science ®Google Scholar
• Hsu JTA, Kuo CJ, Hsieh HP, et al. Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV. FEBS Lett 2004;574:116–20.
   PubMed Web of Science ®Google Scholar
• Han YS, Chang GG, Juo CG, et al. Papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV): expression, purification, characterization, and inhibition. Biochemistry 2005;44:10349–59.
   PubMed Web of Science ®Google Scholar
• Hu F, Wang L, Hu Y, et al. A novel framework integrating AI model and enzymological experiments promotes identification of SARS-CoV-2 3CL protease inhibitors and activity-based probe. Brief Bioinform 2021;22:bbab301.
   PubMed Web of Science ®Google Scholar
• Kuzikov M, Costanzi E, Reinshagen J, et al. Identification of inhibitors of SARS-CoV-2 3CL-Pro enzymatic activity using a small molecule in vitro repurposing screen. ACS Pharmacol Transl Sci 2021;4:1096–110.
   PubMedGoogle Scholar
• Gawish R, Starkl P, Pimenov L, et al. ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNγ-driven immunopathology. Elife 2022;11:e74623.
   PubMed Web of Science ®Google Scholar
• Reeder NL, Xu J, Youngquist RS, et al. The antifungal mechanism of action of zinc pyrithione. Br J Dermatol 2011;165:9–12.
   PubMed Web of Science ®Google Scholar
• Reeder NL, Kaplan J, Xu J, et al. Zinc pyrithione inhibits yeast growth through copper influx and inactivation of iron-sulfur proteins. Antimicrob Agents Chemother 2011;55:5753–60.
   PubMed Web of Science ®Google Scholar
• Park M, Cho YJ, Lee YW, et al. Understanding the mechanism of action of the anti-dandruff agent zinc pyrithione against Malassezia restricta. Sci Rep 2018;8:11.
   PubMed Web of Science ®Google Scholar
• Maio N, Lafont BAP, Sil D, et al. Fe–S cofactors in the SARS-CoV-2 RNA-dependent RNA polymerase are potential antiviral targets. Science 2021;373:236–41.
   PubMed Web of Science ®Google Scholar
• Kljun J, Anko M, Traven K, et al. Pyrithione-based ruthenium complexes as inhibitors of aldo-keto reductase 1C enzymes and anticancer agents. Dalton Trans 2016;45:11791–800.
   PubMed Web of Science ®Google Scholar
• Kladnik J, Kljun J, Burmeister H, et al. Towards identification of essential structural elements of organoruthenium(II)-pyrithionato complexes for anticancer activity. Che Eur J 2019;25:14169–82.
   PubMed Web of Science ®Google Scholar
• Kladnik J, Coverdale JPC, Kljun J, et al. Organoruthenium complexes with benzo-fused pyrithiones overcome platinum resistance in ovarian cancer cells. Cancers 2021;13:2493.
   PubMed Web of Science ®Google Scholar
• Kladnik J, Ristovski S, Kljun J, et al. Structural isomerism and enhanced lipophilicity of pyrithione ligands of organoruthenium(II) complexes increase inhibition on AChE and BuChE. Int J Mol Sci 2020;21:5628.
   PubMed Web of Science ®Google Scholar
• Doose CA, Ranke J, Stock F, et al. Structure–activity relationships of pyrithiones-IPC-81 toxicity tests with the antifouling biocide zinc pyrithione and structural analogues. Green Chem 2004;6:259–66.
   Web of Science ®Google Scholar
• Novinec M, Pavšič M, Lenarčič B. A simple and efficient protocol for the production of recombinant cathepsin V and other cysteine cathepsins in soluble form in Escherichia coli. Protein Expr Purif 2012;82:1–5.
   PubMed Web of Science ®Google Scholar
• Shin D, Mukherjee R, Grewe D, et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 2020;587:657–62.
   PubMed Web of Science ®Google Scholar
• Palmier MO, Van Doren SR. Rapid determination of enzyme kinetics from fluorescence: overcoming the inner filter effect. Anal Biochem 2007;371:43–51.
   PubMed Web of Science ®Google Scholar
• Grau-Expósito J, Perea D, Suppi M, et al. Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells. PLOS Pathog 2022;18:e1010171.
   PubMedGoogle Scholar
• Krężel A, Maret W. The biological inorganic chemistry of zinc ions. Arch Biochem Biophys 2016;611:3–19.
   PubMed Web of Science ®Google Scholar
• Magda D, Lecane P, Wang Z, et al. Synthesis and anticancer properties of water-soluble zinc ionophores. Cancer Res 2008;68:5318–25.
   PubMed Web of Science ®Google Scholar
• Barnett BL, Kretschmar HC, Hartman FA. Structural characterization of bis(N-oxopyridine-2-thionato)zinc(II). Inorg Chem 1977;16:1834–8.
   Web of Science ®Google Scholar
• Niu DZ, Sun BW, Lu ZS, et al. Synthesis and crystal structure of dinuclear zinc(II) complex with 3-Me-N-oxopyridine-2-thiol. Chin J Struct Chem 2001;20:108–11.
   Google Scholar
• Xiong RG, Song BL, You XZ, et al. Syntheses and properties of some transition metal complexes with methyl substituted 1-hydroxy-2(1H)-pyridinethione and crystal structure of bis(1-hydroxy-4-methyl-2(1H)pyridinethionato-O,S′)zinc(II). Polyhedron 1996;15:991–6.
   Web of Science ®Google Scholar
• West DX, Brown CA, Jasinski JP, et al. Crystal structures of the cobalt(III), nickel(II), copper(II), and zinc(II) complexes of 2-thio-6-picoline N-oxide. J Chem Crystallogr 1998;28:853–60.
   Web of Science ®Google Scholar
• de Paiva REF, Marçal Neto A, Santos IA, et al. What is holding back the development of antiviral metallodrugs? A literature overview and implications for SARS-CoV-2 therapeutics and future viral outbreaks. Dalton Trans 2020;49:16004–33.
   PubMed Web of Science ®Google Scholar
• Vogel-González M, Talló-Parra M, Herrera-Fernández V, et al. Low zinc levels at admission associates with poor clinical outcomes in SARS-CoV-2 infection. Nutrients 2021;13:562.
   PubMed Web of Science ®Google Scholar
• Thomas S, Patel D, Bittel B, et al. Effect of high-dose zinc and ascorbic acid supplementation vs usual care on symptom length and reduction among ambulatory patients with SARS-CoV-2 infection: the COVID A to Z randomized clinical trial. JAMA Netw Open 2021;4:e210369.
   PubMed Web of Science ®Google Scholar
• Al Sulaiman K, Aljuhani O, Al Shaya AI, et al. Evaluation of zinc sulfate as an adjunctive therapy in COVID-19 critically ill patients: a two center propensity-score matched study. Crit Care 2021;25:363.
   PubMed Web of Science ®Google Scholar
• Perera M, Khoury JE, Chinni V, et al. Randomised controlled trial for high-dose intravenous zinc as adjunctive therapy in SARS-CoV-2 (COVID-19) positive critically ill patients: trial protocol. BMJ Open 2020;10:e040580.
   PubMedGoogle Scholar
• Patel O, Chinni V, El-Khoury J, et al. A pilot double-blind safety and feasibility randomized controlled trial of high-dose intravenous zinc in hospitalized COVID-19 patients. J Med Virol 2021;93:3261–7.
   PubMed Web of Science ®Google Scholar
• Hoang BX, Han B. A possible application of hinokitiol as a natural zinc ionophore and anti-infective agent for the prevention and treatment of COVID-19 and viral infections. Med Hypotheses 2020;145:110333.
   PubMed Web of Science ®Google Scholar
• Hecel A, Ostrowska M, Stokowa-Sołtys K, et al. Zinc(II)—the overlooked éminence grise of chloroquine’s fight against COVID-19? Pharmaceuticals 2020;13:228.
   Web of Science ®Google Scholar
• Scavo S, Oliveri V. Zinc ionophores: chemistry and biological applications. J Inorg Biochem 2022;228:111691.
   PubMed Web of Science ®Google Scholar
• Frontera JA, Rahimian JO, Yaghi S, et al. Treatment with zinc is associated with reduced in-hospital mortality among COVID-19 patients: a multi-center cohort study. Res Sq 2020.
   Google Scholar
• Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med 2020;383:2041–52.
   PubMed Web of Science ®Google Scholar
• Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:1036–41.
   PubMed Web of Science ®Google Scholar
• Jankelson L, Karam G, Becker ML, et al. QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review. Heart Rhythm 2020;17:1472–9.
   PubMed Web of Science ®Google Scholar
• Barth LM, Rink L, Wessels I. Increase of the intracellular zinc concentration leads to an activation and internalisation of the epidermal growth factor receptor in A549 cells. Int J Mol Sci 2020;22:326.
   PubMed Web of Science ®Google Scholar
• Li G, De Oliveira DMP, Walker MJ. The antimicrobial and immunomodulatory effects of ionophores for the treatment of human infection. J Inorg Biochem 2022;227:111661.
   PubMed Web of Science ®Google Scholar
• Tan H, Hu Y, Jadhav P, et al. Progress and challenges in targeting the SARS-CoV-2 papain-like protease. J Med Chem 2022;65:7561–80.
   PubMed Web of Science ®Google Scholar
• Zhao MM, Yang WL, Yang FY, et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct Target Ther 2021;6:1–12.
   PubMed Web of Science ®Google Scholar
• Liu T, Luo S, Libby P, Shi G-P. Cathepsin L-selective inhibitors: a potentially promising treatment for COVID-19 patients. Pharmacol Ther 2020;213:107587.
   PubMed Web of Science ®Google Scholar
• Osipiuk J, Azizi SA, Dvorkin S, et al. Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. Nat Commun 2021;12:1.
   PubMed Web of Science ®Google Scholar
• de Arruda EGR, Rocha BA, Barrionuevo MVF, et al. The influence of ZnII coordination sphere and chemical structure over the reactivity of metallo-β-lactamase model compounds. Dalton Trans 2019;48:2900–16.
   PubMed Web of Science ®Google Scholar
• Rudzińska M, Parodi A, Soond SM, et al. The role of cysteine cathepsins in cancer progression and drug resistance. Int J Mol Sci 2019;20:3602.
   PubMed Web of Science ®Google Scholar
• Mirza MU, Ahmad S, Abdullah I, et al. Identification of novel human USP2 inhibitor and its putative role in treatment of COVID-19 by inhibiting SARS-CoV-2 papain-like (PLpro) protease. J Bioinform Comput Biol 2020;89:107376.
   Google Scholar
• Wang R, Fuk-Woo Chan J, Suyu Wang B, et al. Orally administered bismuth drug together with N-acetyl cysteine as a broad-spectrum anti-coronavirus cocktail therapy. Chem Sci 2022;13:2238–48.
   PubMed Web of Science ®Google Scholar
• Báez-Santos YM, St John SE, Mesecar AD. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res 2015;115:21–38.
   PubMed Web of Science ®Google Scholar
• Bolognesi ML. Harnessing polypharmacology with medicinal chemistry. ACS Med Chem Lett 2019;10:273–5.
   PubMed Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017;7:42717.
   PubMed Web of Science ®Google Scholar
• Gao Y, Gesenberg C, Zheng W, Oral formulations for preclinical studies: principle, design, and development considerations. In: Qiu Y, Chen Y, Zhang GGZ, et al., eds. Developing solid oral dosage forms: pharmaceutical theory and practice. 2nd ed. New York: Academic Press; 2017:455–95.
   Google Scholar
• Gomez-Orellana I. Strategies to improve oral drug bioavailability. Expert Opin Drug Deliv 2005;2:419–33.
   PubMed Web of Science ®Google Scholar
• Wen H, Jung H, Li X. Drug delivery approaches in addressing clinical pharmacology-related issues: opportunities and challenges. AAPS J 2015;17:1327–40.
   PubMed Web of Science ®Google Scholar
• Kladnik J, Dolinar A, Kljun J, et al. Zinc pyrithione is a potent inhibitor of PLPro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication. bioRxiv; 2022.
   Google Scholar